BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28238953)

  • 1. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
    Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
    Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
    Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening.
    Sami SS; Moriarty JP; Rosedahl JK; Borah BJ; Katzka DA; Wang KK; Kisiel JB; Ragunath K; Rubenstein JH; Iyer PG
    Am J Gastroenterol; 2021 Aug; 116(8):1620-1631. PubMed ID: 34131096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy.
    Eluri S; Paterson A; Lauren BN; O'Donovan M; Bhandari P; di Pietro M; Lee M; Haidry R; Lovat L; Ragunath K; Hur C; Fitzgerald RC; Shaheen NJ
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e51-e63. PubMed ID: 33581357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients.
    Januszewicz W; Tan WK; Lehovsky K; Debiram-Beecham I; Nuckcheddy T; Moist S; Kadri S; di Pietro M; Boussioutas A; Shaheen NJ; Katzka DA; Dellon ES; Fitzgerald RC;
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):647-656.e1. PubMed ID: 30099104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of screening a population with chronic gastroesophageal reflux.
    Nietert PJ; Silverstein MD; Mokhashi MS; Kim CY; Glenn TF; Marsi VA; Hawes RH; Wallace MB
    Gastrointest Endosc; 2003 Mar; 57(3):311-8. PubMed ID: 12612508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
    Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
    Gerson L; Lin OS
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Barrett-Screening: Rational, current concepts and perspectives].
    Weismüller J; Thieme R; Hoffmeister A; Weismüller T; Gockel I
    Z Gastroenterol; 2019 Mar; 57(3):317-326. PubMed ID: 30861556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Barrett's esophagus.
    Spechler SJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S25-9. PubMed ID: 12478241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study.
    Freeman M; Offman J; Walter FM; Sasieni P; Smith SG
    BMJ Open; 2017 Mar; 7(3):e013901. PubMed ID: 28255095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
    Shaheen N; Ransohoff DF
    JAMA; 2002 Apr; 287(15):1972-81. PubMed ID: 11960540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
    Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
    Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Barrett-Screening: Rational, current concepts and perspectives].
    Weismüller J; Thieme R; Hoffmeister A; Weismüller T; Gockel I
    Laryngorhinootologie; 2020 Apr; 99(4):214-223. PubMed ID: 32314335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
    Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
    BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a minimally invasive cell sampling device ('Cytosponge') in the diagnosis of esophageal pathology: a systematic review.
    Iqbal U; Siddique O; Ovalle A; Anwar H; Moss SF
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1261-1269. PubMed ID: 30044236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma.
    Hammad TA; Thrift AP; El-Serag HB; Husain NS
    Dig Dis Sci; 2019 Feb; 64(2):367-372. PubMed ID: 30370493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.